Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion type Assertion NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_head.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion description "[Ten months after the combination therapy thrombocytopenia developed and cytogenetic analysis showed 45,XX,-7, indicating an evolution to myelodysplastic syndrome (MDS) associated with monosomy 7.G-CSF and EPO treatment together with immunosuppression may be an effective therapy in SAA patients, but such a therapy may increase the risk of evolution to MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_provenance.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion evidence source_evidence_literature NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_provenance.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion SIO_000772 8580564 NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_provenance.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion wasDerivedFrom befree-2016 NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_provenance.
- NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_assertion wasGeneratedBy ECO_0000203 NP1346525.RAYvAO4qzZ58hXtaPp9DuPl8o7iU2Dq1h8w7RgEZb4Tb8130_provenance.